Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
42 hedge funds and large institutions have $17.1M invested in Cidara Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 9 closing their positions.
1,200% more call options, than puts
Call options by funds: $13K | Put options by funds: $1K
28% more capital invested
Capital invested by funds: $13.3M → $17.1M (+$3.77M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 1.97% → 1.93% (-0.04%)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
9% less funds holding
Funds holding: 46 → 42 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$255K |
| 2 |
Renaissance Technologies
New York
|
+$94.6K |
| 3 |
TAM
Tocqueville Asset Management
New York
|
+$71.8K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$68.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$57.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$229K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$179K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$102K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$69K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$39.6K |
CDTX Hedge Fund Activity: Q3 2022 in Review
42 of the 5,827 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2022, worth a combined $17.1M — up 28% from $13.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CDTX and 5 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 10 added.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $255K. The largest seller was Point72 Asset Management, cutting an estimated $229K.
- 42 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2022, down from 46 in Q2 2022.
- Funds reported $17.1M of Cidara Therapeutics stock for Q3 2022, up 28% quarter-over-quarter.
- 5 funds opened new Cidara Therapeutics positions in Q3 2022 and 9 closed out, a net change of -4 holders.
- The largest Cidara Therapeutics buyer in Q3 2022 was Monashee Investment Management, an estimated $255K added.
- The largest Cidara Therapeutics seller in Q3 2022 was Point72 Asset Management, an estimated $229K sold.
Based on aggregated 13F filings for Q3 2022.